GlassScriptPhysician profile
Michael T Wiles
NPI 1598853970
$5,063.01
in general payments reported to CMS, 2019-2025
25 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $879 · 2021: $416 · 2022: $490 · 2023: $1,167 · 2024: $939 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,399.57 | 2019-2025 | Puraply, Affinity, Novachor |
| Alpha Orthopedic Systems | $984.57 | 2019-2020 | |
| Smith+Nephew, INC. | $545.83 | 2019-2025 | Grafix Xc, Stravix, Stravix Pl |
| Bone Support INC. | $298.72 | 2024 | Ceramentbone Void Filler, Cerament G |
| Nevro Corp. | $259.68 | 2023 | Senza |
| Paratek Pharmaceuticals, INC. | $219.56 | 2022-2024 | Nuzyra |
| Triad Life Sciences INC. | $197.16 | 2021 | |
| Bsn Medical INC | $193.95 | 2024-2025 | |
| Melinta Therapeutics, LLC | $160.27 | 2019 | |
| Medtronic, INC. | $136.74 | 2021 | |
| Horizon Therapeutics Plc | $115.64 | 2019-2023 | Krystexxa |
| Baxter Healthcare | $94.93 | 2025 | |
| Zimvie INC. | $78.02 | 2022 | |
| Kerecis Limited | $74.47 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Trice Medical, INC. | $58.75 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $52.03 | 2019 | |
| Terumo Medical Corporation | $45.34 | 2019 | |
| Kci USA, INC. | $36.75 | 2022 | |
| Convatec INC. | $21.43 | 2023 | |
| Alfasigma USA, INC. | $20.51 | 2022 | |
| Ibsa Pharma INC. | $17.26 | 2023 | Tirosint, Licart |
| Tenex Health INC. | $15.96 | 2020 | |
| Abbvie INC. | $15.08 | 2023 | Dalvance |
| Treace Medical Concepts, INC. | $15.03 | 2022 | |
| In2bones USA, LLC | $5.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.